Boston Scientific has received FDA approval for its two spinal cord stimulation (SCS) leads for use with its Precision Plus Spinal Cord Stimulator System, the rechargeable SCS device for the management of chronic pain of the trunk and/or limbs.

The Linear 3-4 and Linear 3-6 Percutaneous Leads offer wider contact spacing to expand the lead choices available to physicians.

Boston Scientific said that the SCS leads are designed to deliver electrical pulses from an implantable pulse generator to the spinal cord to mask pain signals to the brain. The new leads, in combination with the recently launched W4 and D4 lead splitters, provide the broadest range of percutaneous lead configurations in the industry.

Boston Scientific has already launched the SCS leads in Europe and other international markets earlier the current year and plans to launch the products immediately in the US.

Michael Onuscheck, senior vice president and president of neuromodulation division at Boston Scientific, said: “Our products are designed to meet the unique clinical demands of SCS pain patients. The approval of these products expands our portfolio of leads for the Precision Plus System, offering pain management physicians more choices to help optimize pain relief for their patients.”